The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | May the force be with you: the power of next-generation sequencing
Clinical access to new technologies, such as next-generation sequencing (NGS), can revolutionize the treatment of cancer. In this interview, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, eloquently highlights the potential of NGS for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Garcia-Manero emphasizes the power of this tool for predictive screening, among a range of other utilities. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
